Neogen Corporation (NEOG)
USD 11.64
(-4.04%)
USD 11.64
(-4.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 182.59 Million USD | 49.31% |
| 2023 | 122.29 Million USD | -36.0% |
| 2022 | 107.89 Million USD | -20.97% |
| 2021 | 98.29 Million USD | 9.84% |
| 2020 | 85.91 Million USD | -0.84% |
| 2019 | 85.71 Million USD | -2.99% |
| 2018 | 87.25 Million USD | 8.08% |
| 2017 | 79.63 Million USD | 15.18% |
| 2016 | 56.38 Million USD | 6.15% |
| 2015 | 63.76 Million USD | 22.42% |
| 2014 | 52.57 Million USD | 6.6% |
| 2013 | 48.11 Million USD | 20.65% |
| 2012 | 39.91 Million USD | -19.39% |
| 2011 | 41.16 Million USD | 58.32% |
| 2010 | 31.31 Million USD | 36.61% |
| 2009 | 24.37 Million USD | -9.98% |
| 2008 | 21.53 Million USD | 31.64% |
| 2007 | 16.34 Million USD | 14.9% |
| 2006 | 14.46 Million USD | 38.68% |
| 2005 | 10.47 Million USD | 16.48% |
| 2004 | 8.94 Million USD | 16.84% |
| 2003 | 7.92 Million USD | 20.69% |
| 2002 | 6.57 Million USD | 17.6% |
| 2001 | 5.56 Million USD | 173.93% |
| 2000 | 3.3 Million USD | -49.03% |
| 1999 | 3.47 Million USD | 171.43% |
| 1998 | 2.28 Million USD | 0.0% |
| 1997 | 2 Million USD | -6.67% |
| 1996 | 1 Million USD | 66.67% |
| 1995 | 1.1 Million USD | -30.77% |
| 1994 | 1.3 Million USD | 316.67% |
| 1993 | -400 Thousand USD | 33.33% |
| 1992 | -700 Thousand USD | 43.75% |
| 1991 | -1 Million USD | -42.86% |
| 1990 | -700 Thousand USD | -800.0% |
| 1989 | 100 Thousand USD | 120.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 43.02 Million USD | -14.11% |
| 2024 Q2 | 45.97 Million USD | -1.16% |
| 2024 Q4 | 46.43 Million USD | -0.0% |
| 2024 Q1 | 47.86 Million USD | -58.05% |
| 2024 FY | - USD | 429.53% |
| 2023 Q1 | 6.06 Million USD | -66.37% |
| 2023 Q2 | -7.65 Million USD | -226.29% |
| 2023 FY | - USD | -36.0% |
| 2023 Q3 | 15.68 Million USD | 304.86% |
| 2023 Q4 | 23.42 Million USD | 49.36% |
| 2022 Q3 | 6.37 Million USD | -48.86% |
| 2022 Q1 | 21.74 Million USD | 7.36% |
| 2022 Q4 | 18.02 Million USD | 182.69% |
| 2022 FY | - USD | -20.97% |
| 2022 Q2 | 12.46 Million USD | -42.66% |
| 2021 Q3 | 15.77 Million USD | -18.04% |
| 2021 FY | - USD | 9.84% |
| 2021 Q4 | 20.25 Million USD | 28.41% |
| 2021 Q2 | 19.24 Million USD | 1.85% |
| 2021 Q1 | 18.89 Million USD | -5.26% |
| 2020 Q4 | 19.94 Million USD | 52.91% |
| 2020 FY | - USD | -0.84% |
| 2020 Q1 | 20.69 Million USD | 10.51% |
| 2020 Q2 | 18.27 Million USD | -11.73% |
| 2020 Q3 | 13.04 Million USD | -28.62% |
| 2019 Q2 | 18.24 Million USD | 10.72% |
| 2019 Q1 | 16.47 Million USD | -17.02% |
| 2019 Q4 | 18.73 Million USD | 27.95% |
| 2019 Q3 | 14.63 Million USD | -19.77% |
| 2019 FY | - USD | -2.99% |
| 2018 Q1 | 16.42 Million USD | -13.56% |
| 2018 Q4 | 19.85 Million USD | 24.8% |
| 2018 Q3 | 15.91 Million USD | -11.58% |
| 2018 Q2 | 17.99 Million USD | 9.58% |
| 2018 FY | - USD | 8.08% |
| 2017 Q2 | 16.85 Million USD | 14.31% |
| 2017 FY | - USD | 15.18% |
| 2017 Q3 | 14.35 Million USD | -14.84% |
| 2017 Q4 | 19 Million USD | 32.39% |
| 2017 Q1 | 14.74 Million USD | -5.65% |
| 2016 FY | - USD | 6.15% |
| 2016 Q4 | 15.62 Million USD | 38.84% |
| 2016 Q1 | 14.89 Million USD | 1.87% |
| 2016 Q2 | 14.61 Million USD | -1.9% |
| 2016 Q3 | 11.25 Million USD | -22.98% |
| 2015 FY | - USD | 22.42% |
| 2015 Q4 | 14.62 Million USD | -2.04% |
| 2015 Q2 | 12.89 Million USD | -4.03% |
| 2015 Q3 | 14.92 Million USD | 15.73% |
| 2015 Q1 | 13.43 Million USD | 22.27% |
| 2014 Q3 | 10.29 Million USD | 6.23% |
| 2014 FY | - USD | 6.6% |
| 2014 Q1 | 12.41 Million USD | 21.33% |
| 2014 Q2 | 9.68 Million USD | -21.98% |
| 2014 Q4 | 10.99 Million USD | 6.78% |
| 2013 Q2 | 10.47 Million USD | 1.44% |
| 2013 Q4 | 10.23 Million USD | 5.89% |
| 2013 FY | - USD | 20.65% |
| 2013 Q1 | 10.32 Million USD | 18.75% |
| 2013 Q3 | 9.66 Million USD | -7.74% |
| 2012 Q2 | 8.14 Million USD | -13.27% |
| 2012 FY | - USD | -19.39% |
| 2012 Q4 | 8.69 Million USD | 25.06% |
| 2012 Q3 | 6.95 Million USD | -14.66% |
| 2012 Q1 | 9.39 Million USD | -4.53% |
| 2011 Q1 | 9.96 Million USD | 26.43% |
| 2011 Q2 | 11.1 Million USD | 11.37% |
| 2011 Q3 | 8.28 Million USD | -25.35% |
| 2011 Q4 | 9.84 Million USD | 18.76% |
| 2011 FY | - USD | 58.32% |
| 2010 Q4 | 7.88 Million USD | 37.9% |
| 2010 Q1 | 6.89 Million USD | 8.3% |
| 2010 Q2 | 7.24 Million USD | 5.12% |
| 2010 Q3 | 5.71 Million USD | -21.1% |
| 2010 FY | - USD | 36.61% |
| 2009 Q1 | 6.46 Million USD | 13.27% |
| 2009 FY | - USD | -9.98% |
| 2009 Q2 | 6.69 Million USD | 3.58% |
| 2009 Q3 | 3.97 Million USD | -40.66% |
| 2009 Q4 | 6.36 Million USD | 60.29% |
| 2008 Q3 | 5 Million USD | -7.46% |
| 2008 Q4 | 5.7 Million USD | 13.88% |
| 2008 FY | - USD | 31.64% |
| 2008 Q1 | 5.37 Million USD | 37.44% |
| 2008 Q2 | 5.41 Million USD | 0.78% |
| 2007 FY | - USD | 14.9% |
| 2007 Q4 | 3.9 Million USD | 10.36% |
| 2007 Q3 | 3.54 Million USD | -21.92% |
| 2007 Q2 | 4.53 Million USD | 4.32% |
| 2007 Q1 | 4.34 Million USD | 7.2% |
| 2006 Q1 | 3.42 Million USD | 34.0% |
| 2006 Q2 | 3.78 Million USD | 10.41% |
| 2006 Q3 | 2.94 Million USD | -22.29% |
| 2006 Q4 | 4.05 Million USD | 37.83% |
| 2006 FY | - USD | 38.68% |
| 2005 Q4 | 2.55 Million USD | 15.74% |
| 2005 Q3 | 2.21 Million USD | -15.8% |
| 2005 Q2 | 2.62 Million USD | -7.96% |
| 2005 Q1 | 2.85 Million USD | 35.28% |
| 2005 FY | - USD | 16.48% |
| 2004 Q1 | 2.09 Million USD | 10.63% |
| 2004 FY | - USD | 16.84% |
| 2004 Q4 | 2.1 Million USD | 3.03% |
| 2004 Q3 | 2.04 Million USD | -19.79% |
| 2004 Q2 | 2.55 Million USD | 22.05% |
| 2003 Q1 | 1.83 Million USD | 5.1% |
| 2003 Q2 | 2.36 Million USD | 30.77% |
| 2003 Q3 | 1.73 Million USD | -27.42% |
| 2003 Q4 | 1.98 Million USD | 14.96% |
| 2003 FY | - USD | 20.69% |
| 2002 Q1 | 1.5 Million USD | -10.58% |
| 2002 Q3 | 1.42 Million USD | -27.93% |
| 2002 Q4 | 1.72 Million USD | 24.28% |
| 2002 Q2 | 1.92 Million USD | 28.85% |
| 2002 FY | - USD | 17.6% |
| 2001 Q1 | 1.13 Million USD | 681.97% |
| 2001 Q2 | 1.5 Million USD | 33.52% |
| 2001 Q3 | 1.29 Million USD | -13.43% |
| 2001 Q4 | 1.64 Million USD | 29.73% |
| 2001 FY | - USD | 173.93% |
| 2000 Q1 | 800 Thousand USD | -53.33% |
| 2000 FY | - USD | -49.03% |
| 2000 Q4 | 981 Thousand USD | -119.57% |
| 2000 Q3 | 992 Thousand USD | 211.67% |
| 2000 Q2 | 400 Thousand USD | -57.14% |
| 1999 Q3 | 1 Million USD | 14.29% |
| 1999 FY | - USD | 171.43% |
| 1999 Q1 | 5.7 Million USD | 1800.0% |
| 1999 Q2 | 1 Million USD | -87.72% |
| 1999 Q4 | 600 Thousand USD | 87.5% |
| 1998 Q3 | 600 Thousand USD | 33.33% |
| 1998 Q4 | 500 Thousand USD | -25.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q2 | 500 Thousand USD | -25.0% |
| 1998 Q1 | 600 Thousand USD | 33.33% |
| 1997 Q2 | 600 Thousand USD | -16.67% |
| 1997 FY | - USD | -6.67% |
| 1997 Q4 | 500 Thousand USD | 200.0% |
| 1997 Q1 | 600 Thousand USD | -14.29% |
| 1997 Q3 | 400 Thousand USD | -80.0% |
| 1996 Q4 | 700 Thousand USD | 250.0% |
| 1996 FY | - USD | 66.67% |
| 1996 Q3 | 200 Thousand USD | -33.33% |
| 1996 Q2 | 300 Thousand USD | 200.0% |
| 1996 Q1 | 100 Thousand USD | 101.25% |
| 1995 Q1 | 2.6 Million USD | 136.62% |
| 1995 Q2 | 2.9 Million USD | 11.54% |
| 1995 Q3 | 3 Million USD | 3.45% |
| 1995 FY | - USD | -30.77% |
| 1995 Q4 | -8 Million USD | -366.67% |
| 1994 FY | - USD | 316.67% |
| 1994 Q2 | 500 Thousand USD | 200.0% |
| 1994 Q3 | 2.7 Million USD | 350.0% |
| 1994 Q4 | -7.1 Million USD | -362.96% |
| 1994 Q1 | 200 Thousand USD | 103.28% |
| 1993 FY | - USD | 33.33% |
| 1993 Q4 | -6.1 Million USD | -390.48% |
| 1993 Q3 | 2.1 Million USD | 10.53% |
| 1993 Q2 | 1.9 Million USD | 1050.0% |
| 1993 Q1 | -200 Thousand USD | 96.55% |
| 1992 Q4 | -5.8 Million USD | -422.22% |
| 1992 FY | - USD | 43.75% |
| 1992 Q3 | 1.8 Million USD | 5.88% |
| 1992 Q2 | 1.7 Million USD | 30.77% |
| 1992 Q1 | 1.3 Million USD | 124.53% |
| 1991 Q2 | 1.5 Million USD | 36.36% |
| 1991 Q3 | 1.5 Million USD | 0.0% |
| 1991 FY | - USD | 5.88% |
| 1991 Q4 | -5.3 Million USD | -453.33% |
| 1991 Q1 | 1.1 Million USD | 120.37% |
| 1990 Q1 | 1.2 Million USD | 125.0% |
| 1990 Q3 | 1.4 Million USD | -12.5% |
| 1990 Q2 | 1.6 Million USD | 33.33% |
| 1990 Q4 | -5.4 Million USD | -485.71% |
| 1990 FY | - USD | -1800.0% |
| 1989 Q3 | 1.5 Million USD | -6.25% |
| 1989 FY | - USD | 125.0% |
| 1989 Q4 | -4.8 Million USD | -420.0% |
| 1989 Q1 | 1.5 Million USD | 134.09% |
| 1989 Q2 | 1.6 Million USD | 6.67% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 185.484% |
| Prenetics Global Limited | -47.89 Million USD | 481.236% |
| Star Equity Holdings, Inc. | -1.68 Million USD | 10923.77% |
| CareDx, Inc | -89.65 Million USD | 303.662% |
| Exact Sciences Corporation | 41.87 Million USD | -336.042% |
| Exagen Inc. | -19.15 Million USD | 1053.36% |
| Inotiv, Inc. | -26.5 Million USD | 788.889% |
| Guardant Health, Inc. | -433.3 Million USD | 142.141% |
| Biodesix, Inc. | -37.1 Million USD | 592.135% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | 7447.492% |
| Precipio, Inc. | -4.31 Million USD | 4328.74% |
| iSpecimen Inc. | -9.1 Million USD | 2105.741% |
| Natera, Inc. | -383.27 Million USD | 147.641% |
| Aspira Women's Health Inc. | -16.49 Million USD | 1207.252% |
| Standard BioTools Inc. | -54.45 Million USD | 435.305% |
| 23andMe Holding Co. | -291.87 Million USD | 162.56% |
| Castle Biosciences, Inc. | -45.02 Million USD | 505.555% |
| Personalis, Inc. | -96.8 Million USD | 288.62% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 255.316% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | 2003.829% |
| OpGen, Inc. | -29.51 Million USD | 718.742% |
| T2 Biosystems, Inc. | -43.87 Million USD | 516.175% |
| Myriad Genetics, Inc. | -67.8 Million USD | 369.317% |
| ICON Public Limited Company | 1.63 Billion USD | 88.809% |
| NeoGenomics, Inc. | -17.6 Million USD | 1137.07% |
| Star Equity Holdings, Inc. | -1.68 Million USD | 10923.77% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 85.004% |
| RadNet, Inc. | 292.78 Million USD | 37.635% |
| MDxHealth SA | -30.46 Million USD | 699.307% |
| Psychemedics Corporation | -251 Thousand USD | 72847.809% |
| Illumina, Inc. | -608 Million USD | 130.032% |
| Check-Cap Ltd. | -17.64 Million USD | 1134.603% |
| Twist Bioscience Corporation | -176.7 Million USD | 203.334% |
| DarioHealth Corp. | -53.49 Million USD | 441.341% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 492.243% |
| Sera Prognostics, Inc. | -35.28 Million USD | 617.463% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | 1966.128% |
| OPKO Health, Inc. | -65.51 Million USD | 378.706% |
| Medpace Holdings, Inc. | 363.15 Million USD | 49.719% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | 2172.444% |
| Prenetics Global Limited | -47.89 Million USD | 481.236% |
| Mainz Biomed B.V. | -25.01 Million USD | 830.061% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 2493.363% |
| Trinity Biotech plc | -24.09 Million USD | 857.727% |
| Neuronetics, Inc. | -22.75 Million USD | 902.307% |
| Sotera Health Company | 514.14 Million USD | 64.485% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 2493.363% |